CMPS — COMPASS Pathways Share News
0.000.00%
Last trade - 00:00Corrected: Compass Pathways Q3 net loss narrows on lower R&D charges
Corrected: BRIEF-COMPASS Pathways Q3 EPS USD -0.31
Psychedelic drug developers fall after Usona submits depressive drug application
Compass Pathways PLC expected to post a loss of 45 cents a share - Earnings Preview
Brief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Explainer: As Trump backs psychedelics research, FDA weighs safety and access standards
Corrected: UPDATE 2-Experts urge FDA to set clear safety and access standards for psychedelic drugs (September 14)
FDA to hold public hearing on psychedelic drugs as Trump-driven push gathers pace
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
U.S. STOCKS ON THE MOVE-UGI, Chewy, Cognyte Software
Compass Pathways rises after one-year data for psychedelic-based depression drug
Compass Pathways PLC reports results for the quarter ended June 30 - Earnings Summary
Compass Pathways' Q2 loss widens on commercial readiness activity costs
Brief: COMPASS Pathways Q2 EPS USD -1.88
Compass Pathways PLC expected to post a loss of 40 cents a share - Earnings Preview
Compass Pathways PLC expected to post a loss of 40 cents a share - Earnings Preview
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
U.S. STOCKS ON THE MOVE-Vera Therapeutics, Vera Therapeutics, Nvidia